Bifogade filer
2cureX presents preliminary Q1 2023 commercial results.
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX will today, at a Q&A session, present commercial results for Q1 2023 and other important achievements in this quarter.
In summary Q1 2023 has been an active quarter with achievements that are in line with the forecasted goals, except for the number of samples tested, which is slightly lower than forecasted. Other important achievements are above our expectations. We therefore maintain our commercial goals for the full year of 2023.
2023 commercial goals:
Revenue: 6M SEK (0.8 m SEK in Q1)
Commercial rollout: 25 countries with IndiTreat® commercial activities (20 countries in Q1)
Samples tested: 500 patient samples (25 samples in Q1)
Preliminary results for Q1 2023 related to the yearly goals:
Revenue: 0.76 M SEK
Commercial rollout: 20 countries with active IndiTreat® activities
Samples tested: 18 patient samples
Other important achievements in Q1 2023:
A highly successful ISO13485 Audit.
Launch of an updated Specimen Collection Set
IGNITE sites grew from 24 to 27
2cureX received together with technology partners, a prestigious grant (1 M EUR) from the German Federal Ministry of Education and Research to support the automation project.
2cureX received an innovation grant (1.5 M DKK) from the Danish Innovation Foundation Fund to support the development of IndiTreat® Neo.
Strengthened communication activities involving events hosted by Infront Direkt and Stokk.io, a new website, monthly Newsletters and CEO Blogs
The official Q1 2023 report will be published on May 25, 2023.
A Q&A session to present these results in detail, as well as answering questions from the audience, will be held at 20:00 (CET) tonight. You can sign-up for the event with link: Q&A webcast for Q1 2023).